What's hot
View all perspectives
sheila RHEUMarampa
9 months 3 weeks ago
Dr @andreafava presents their noninvasive biomarker panel that predicted the probability of histologically active LN.
Panel outperformed UPCR, C3, C4 & antidsDNA.
Aid in clinical-decision making? Lots of potential for monitoring tx response.
@Rheumnow #ACR24 abs1642
#ACRbest https://t.co/C7ZNdvbIQ7
Eric Dein ericdeinmd
9 months 3 weeks ago
@LennMcD
@ACRheumDC
Many ACR priorities in bills, needs to be passed in law
Victories:
Incr NIH biomedical research funding, added to DoD funds
Medicare reimbursem and telehealth needs addressed by lame duck congress
Get involved, reach out, write letters
@RheumNow #ACR24 https://t.co/7oCvUFWpx4
Mike Putman EBRheum
9 months 3 weeks ago
Impressive Plenary @andreafava just finished Novel urine protein panel id 12 proteins that predict NIH activity on renal bx better than existing options Improving at 3 mos predicts response at 1 year Could reduce biopsies / modulate tx! #ACR24 @RheumNow Abstr#1642 #ACRbest https://t.co/Gi6u6hAGzj
Mike Putman EBRheum
9 months 3 weeks ago
"We look forward to Carol Langfords upcoming leadership at ACR and its newfound focus on ANCA vasculitis as the most important disease" 😆😂
-Phil Seo
#ACR24 @RheumNow
Antoni Chan MD (Prof) synovialjoints
9 months 3 weeks ago
A study presents a novel urinary biomarker panel that predicts histologically active lupus nephritis (LN) with high accuracy.
Key findings:
- AUC of 90% for predicting NIH Activity Index > 2, outperforming traditional biomarkers.
- Identified 12 critical proteins linked to… https://t.co/6ZhqNaxpQM
Adela Castro AdelaCastro222
9 months 3 weeks ago
The 3-4-5 rule for positive MRI in axSpA remains.
The MRI lesion cut-offs demonstrated high performance across different features of axSpA (PsO, AAU,IBD).
Deep fat and deep sclerosis high specificity for axSpA.
#Abst0821 #ACR24 @RheumNow https://t.co/4JM5MHrB8z
Eric Dein ericdeinmd
9 months 3 weeks ago
Starting soon:
Room 152A
@ACRheumDC @cdowneymd @BelindaBirnbaum
What does the election and current political changes mean for rheumatology?
How does ACR play a role in supporting you? What are the easy steps you can do?
#ACR24 @RheumNow https://t.co/jTtk80RdqI
sheila RHEUMarampa
9 months 3 weeks ago
Thrilled to have my abstract accepted for poster presentation at #ACR24 with @rheumarhyme
Drop by abs1314 to know more 🤓
#HPEd #educator #telerheumatology
@Rheumnow https://t.co/j2rZLGm7lA
Antoni Chan MD (Prof) synovialjoints
9 months 3 weeks ago
Managing DMARDs in pregnancy. Curbside consults by Lisa Sammaritano @RheumNow #ACR24 https://t.co/FQrLNz4yCz
Caoilfhionn Connolly CaoilfhionnMD
9 months 3 weeks ago
🫁RP-ILD a/w high morbidity and mortality
How to Predict RP-ILD Development?
➡️AutoAb: anti-MDA5, anti-ARS, anti-Ro52
➡️Biomarkers: CRP, LD, Ferritin, KL-6
➡️CT: Lower consolidation/GGO
#ACR24 @RheumNow https://t.co/OIrHfVTZcM
The SELECT-GCA study, looking at upadacitinib in GCA, anchored the ACR 2024 opening plenary for a reason - it is highly notable and badly needed.
Lupus nephritis is one of the most silent and severe manifestations of SLE. When not captured early, patients are at high risk of progressing to end-stage renal disease, which would require dialysis or transplantation. Renal biopsy remains the gold standard for diagnosis and disease classification. However, the procedure is invasive and very painful. Non-invasive measures are critical for early detection and continuous monitoring.
When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results from this NEJM case series replicate at scale, but it seems likely that CAR-T will revolutionize the care for (some) patients with rheumatic diseases. What new data will be presented at ACR?
Poster Hall